Reconem tablet
Searching the Web
Reconem tablet uses composition dosage
Reading File
Searching the Web
Reconem tablet India pharmaceutical ingredients
Finding Sources
Reading Web Page
https://pharmeasy.in/online-medicine-order/reconil-200mg-tab…
Searching the Web
"Reconem" tablet drug composition uses site:1mg.com OR site:pharmeasy.in OR site:practo.com
Reading Web Page
https://pharmeasy.in/online-medicine-order/browse?alphabet=r…
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Searching the Web
faropenem sodium 200mg tablet uses dosage mechanism of action India
Reading Web Page
https://www.sterispharma.com/ernakulam/latest-update/faropen…
Finding Sources
Here is a complete profile of Reconem tablet:
Reconem (Faropenem Sodium) - Complete Drug Profile
Manufacturer: Lupin Limited, Mumbai
Available Strengths: 200 mg and 300 mg Extended-Release (ER) Tablets
Price: Rs. 750/- for 10 tablets (200 mg)
Schedule: Rx (Prescription only)
Drug Class
Faropenem is an orally active beta-lactam antibiotic belonging to the penem group - structurally related to both carbapenems and cephalosporins, making it unique as one of the few oral drugs in this class.
Mechanism of Action
Faropenem works by inhibiting bacterial cell wall synthesis. It binds to Penicillin-Binding Proteins (PBPs) - enzymes responsible for peptidoglycan cross-linking in bacterial cell walls. By blocking transpeptidation, it disrupts cell wall integrity and exerts bactericidal (bacteria-killing) activity. Key advantages:
- Resistant to ESBLs (Extended-Spectrum Beta-Lactamases)
- Resistant to AmpC beta-lactamases
- Effective against both aerobic and anaerobic bacteria
Spectrum of Activity
- Gram-positive aerobes and anaerobes
- Gram-negative aerobes and anaerobes
- ESBL-producing organisms
- Broad spectrum comparable to carbapenems, with oral availability
Indications (as on label)
| Infection | Details |
|---|---|
| Respiratory Tract Infections | Upper and lower RTIs, Community-Acquired Bacterial Pneumonia (CABP), Acute Bacterial Rhinosinusitis (ABRS) |
| Urinary Tract Infections (UTI) | Including complicated UTIs |
| Skin & Skin Structure Infections | Soft tissue infections |
| Gynaecological Infections | Pelvic infections |
Dosage
| Indication | Dose |
|---|---|
| Upper RTI / Skin / Gynaecological | 150-200 mg TID (three times daily) |
| Lower RTI / ENT / UTI / Genitourinary | 200-300 mg TID |
| Elderly (starting dose) | 150 mg (lower due to reduced renal clearance) |
- Taken orally, in divided doses
- Duration depends on severity and clinical/bacteriological response
Pharmacokinetics
- Good oral bioavailability - rapidly absorbed from the GI tract
- 50% plasma protein bound; extensively tissue distributed
- Metabolized in the liver
- Excreted renally - dose adjustment needed in renal impairment
- Eliminated more slowly in elderly patients
Side Effects
| System | Effects |
|---|---|
| GI (common) | Nausea, abdominal pain, diarrhea, loose stools |
| Skin | Rash, itching |
| CNS | Headache |
| General | Sweating, vitamin deficiency |
| Rare | Candidiasis (superinfection), elevated liver enzymes |
Contraindications
- Hypersensitivity to faropenem or any beta-lactam antibiotic (penicillins, cephalosporins - cross-reactivity possible)
- Should not be used for viral infections
Precautions & Warnings
- Use with caution in renal impairment (increased plasma concentrations)
- Elderly patients: start at 150 mg, monitor for diarrhea
- Caution in pregnancy and breastfeeding
- Monitor liver function with prolonged use
- Caution in diabetic patients
Drug Interactions
- Valproic acid (sodium valproate): Faropenem (like other beta-lactams/carbapenems) can reduce valproate blood levels, risking seizure recurrence - important interaction
- Imipenem + cilastatin: Cilastatin inhibits faropenem metabolism, raising its plasma levels
- Furosemide: May increase renal toxicity of faropenem
Why Faropenem (Reconem) vs. Other Antibiotics?
Reconem's tagline "Recovery Reinforced" reflects its position as a step-up oral beta-lactam for infections where common oral antibiotics (amoxicillin, cephalexin) may fail due to ESBL resistance - offering near-carbapenem-class coverage in tablet form, which is a significant clinical advantage for outpatient management of resistant infections.
Sources: Medindia Faropenem monograph | Goodman & Gilman's Pharmacological Basis of Therapeutics (beta-lactam class)This is the same Reconem (Faropenem Sodium) promotional leaflet by Lupin. I already have comprehensive details from our previous session. Here's a full summary based on what's visible in the image and the research already done:
Reconem - Faropenem Sodium Tablets (Lupin)
What's on the Leaflet
| Detail | Info |
|---|---|
| Brand Name | Reconem |
| Generic Name | Faropenem Sodium |
| Strengths | 200 mg / 300 mg ER Tablets |
| Manufacturer | Lupin Limited, Mumbai |
| Price | Rs. 750/- for 10 tablets (200 mg) |
| Pack | 1 × 10 Tablets |
| Schedule | Rx (Prescription only) |
| Tagline | "Recovery Reinforced" |
Drug Class
Faropenem is an orally active beta-lactam antibiotic of the penem group - the only oral antibiotic with near-carbapenem spectrum coverage. It bridges the gap between oral cephalosporins and IV carbapenems.
Mechanism of Action
- Binds to Penicillin-Binding Proteins (PBPs)
- Inhibits peptidoglycan cross-linking → disrupts bacterial cell wall synthesis → bactericidal activity
- Stable against ESBLs (Extended-Spectrum Beta-Lactamases) and AmpC beta-lactamases
- Active against Gram-positive, Gram-negative, aerobic and anaerobic bacteria
Indications (from label)
| Indication | Notes |
|---|---|
| Respiratory Tract Infections | ABRS (Acute Bacterial Rhinosinusitis), CABP (Community-Acquired Bacterial Pneumonia) |
| Urinary Tract Infections | Including UTIs caused by ESBL organisms |
| Skin Infections | Skin & soft tissue infections |
| Gynaecological Infections | Pelvic/genital tract infections |
Dosage
| Indication | Dose |
|---|---|
| Upper RTI / Skin / Gynaecological | 150-200 mg three times daily (TID) |
| Lower RTI / UTI / ENT | 200-300 mg TID |
| Elderly patients | Start at 150 mg (reduced renal clearance) |
- Taken orally, in divided doses
- Duration based on clinical and bacteriological response
Side Effects
- Common (GI): Nausea, diarrhea, abdominal pain, loose stools
- Skin: Rash, itching
- CNS: Headache
- Rare: Candidiasis (superinfection), elevated liver enzymes
Key Precautions
- Renal impairment: Dose reduction needed (drug accumulates)
- Elderly: Monitor carefully; start low
- Pregnancy/Breastfeeding: Use with caution
- Cross-allergy: Avoid if allergic to penicillins or cephalosporins
- Diabetic patients: Use with caution
Important Drug Interactions
| Drug | Interaction |
|---|---|
| Valproic acid (anti-epileptic) | Faropenem reduces valproate levels → risk of seizure recurrence |
| Imipenem + Cilastatin | Cilastatin blocks faropenem metabolism → increased drug levels |
| Furosemide | Increased risk of renal toxicity |
Abbreviations on the Leaflet
- ABRS - Acute Bacterial Rhinosinusitis
- CABP - Community-Acquired Bacterial Pneumonia
- UTI - Urinary Tract Infection
- TEAE - Treatment-Emergent Adverse Events
- SAE - Serious Adverse Event
- ESBL - Extended-Spectrum Beta-Lactamases
- AmpC - Ambler Class C beta-Lactamase
References Cited on the Leaflet
- Pal A, Pawar D, Sharma A - Faropenem for management of infectious diseases (systematic review) - Journal of Laboratory Physicians, 2025
- Ghosh A et al. - Safety and Efficacy in Respiratory and Urinary Tract Infections (Pediatric) - Journal of Pediatrics, 2025
- Nayak S, Pai U, Birla A - Role of Faropenem in pediatric infections - Cureus, 2022
This is a shared conversation. Sign in to Orris to start your own chat.